OncoSil Achieves Milestone: First Patient Treated in PANCOSIL Trial for Pancreatic Cancer

OncoSil Medical Ltd (ASX: OSL) has successfully treated the first patient in its PANCOSIL Investigator Initiated Clinical Trial in Amsterdam, marking a milestone in local advanced pancreatic cancer (LAPC) treatment. The trial, focusing on the safety and feasibility of OncoSil's device via percutaneous application, received ethics approval in June 2023. Over 20 patients will undergo percutaneous OncoSil™ device treatment, aiming to assess safety and expand user accessibility.

Professor Martijn Meijerink expressed excitement over the CT-guided procedure's potential advantages, emphasizing precision in placing radioactive microparticles. CEO Nigel Lange highlighted the study's significance in commercializing OncoSil™, anticipating alternative implantation techniques and increased accessibility for medical professionals in LAPC treatment.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com